Apixaban

CAS Number503612-47-3
Molecular FormulaC25H25N5O4
Molecular Weight458.5
InChI KeyQNZCBYKSOIHPEH-UHFFFAOYSA-N
LogP0.2
Synonyms
  • Apixaban
  • 503612-47-3
  • Eliquis
  • BMS-562247-01
  • BMS-562247
  • BMS 562247-01
  • 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  • apixabanum
  • 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  • 3Z9Y7UWC1J
  • CHEBI:72296
  • DTXSID80436500
  • BMS562247
  • 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide,4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-
  • 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo(3,4-c)pyridine-3-carboxamide
  • RefChem:5558
  • ELIQUIS 30-Day Starter Pack
  • B01AF02
  • DTXCID60387324
  • 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-
  • MFCD11977295
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
  • Apixaban 13CD3
  • C25H25N5O4
  • CHEMBL231779
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[5,4-c]pyridine-3-carboxamide
  • Apixaban [USAN]
  • GG2
  • Eliquis (TN)
  • UNII-3Z9Y7UWC1J
  • Apixaban (JAN/USAN/INN)
  • Apixaban [USAN:INN:JAN]
  • HSDB 8223
  • Apixaban (Standard)
  • BMS 562247
  • APIXABAN [INN]
  • APIXABAN [JAN]
  • APIXABAN [MI]
  • APIXABAN [VANDF]
  • APIXABAN [MART.]
  • APIXABAN [WHO-DD]
  • APIXABAN [EMA EPAR]
  • Apixaban - Bio-X trade mark
  • MLS006010026
  • SCHEMBL118023
  • APIXABAN [ORANGE BOOK]
  • GTPL6390
  • orb1307573
  • Apixaban,BMS-562247-01
  • BDBM19023
  • EX-A048
  • 2p16
  • QNZCBYKSOIHPEH-UHFFFAOYSA-N
  • HMS3655O07
  • HMS5079A18
  • 503612-47-3, Eliquis,
  • Apixaban (BMS 562247-01)
  • HY-50667R
  • MSK159567
  • NSC784102
  • s1593
  • Apixaban (BMS 562247-01)?
  • AKOS005146204
  • CCG-229675
  • CS-0401
  • DB06605
  • FM61539
  • ME-0152
  • NSC-784102
  • PB10976
  • NCGC00346555-01
  • NCGC00346555-02
  • NCGC00346555-05
  • NCGC00346555-08
  • 1-(4-Methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidyl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
  • AC-26301
  • BM164185
  • HY-50667
  • SMR004676529
  • SY097159
  • NS00014946
  • SW220177-1
  • D03213
  • AB01565766_02
  • 612A473
  • AR-270/43507990
  • Q414462
  • BRD-K67121414-001-02-5
  • BRD-K67121414-001-03-3
  • Z195110238
  • 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXOPIPERIDIN-1-YL)PHENYI)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO(3,4-C)PYRIDINE-3-CARBOXAMIDE
  • 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo(3,4c)pyridine-3-carboxamide
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
  • 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  • 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide?BMS-562247; BMS-562247-01
  • 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide;BMS 562247-01
  • 1H-PYRAZOLO(3,4-C)PYRIDINE-3-CARBOXAMIDE, 4,5,6,7-TETRAHYDRO-1-( 4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-

Applications:

Analysis of Eliquis (Apixaban) on Primesep B Column on Alltesta™

December 1, 2025

HPLC Method for Apixaban on Primesep B by SIELC Technologies


High Performance Liquid Chromatography (HPLC) Method for Analysis of Apixaban 

Apixaban is an anticoagulant medication with the chemical formula C25H25N5O4. It is used primarily to treat and prevent blood clots and stroke. It works through directly inhibiting factor Xa. In patients who have undergone knee or hop replacement surgery, apixaban helps prevent deep vein thrombosis.

Apixaban can be retained and analyzed using the Primesep B stationary phase column. The analysis utilizes an isocratic method with a simple mobile phase consisting of water and acetonitrile (MeCN) with phosphoric acid as a buffer. Detection is performed using UV.

ColumnPrimesep B, 4.6 x 150 mm, 5 µm, 100 A, dual ended
Mobile PhaseMeCN – 30%
BufferAmmonium Formate
Flow Rate1.0 mL/min
DetectionUV 275 nm
Class of CompoundsDrug
Analyzing CompoundsApixaban

Application Column

Primesep B

Column Diameter: 4.6 mm
Column Length: 150 mm
Particle Size: 5 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Apixaban
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.